» COVID-19 Information


Manage your account, request prescriptions, set up appointments & more.

Don't have an account
Contact Us
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label



Clinical Trial Title

Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma

Trial Status

Closed to Enrollment

Start Date

April 20, 2012

Trial Type

Pediatric Cancer (Oncology)

Specific Condition

Diffuse Intrinsic Pontine Gliomas (DIPG)


This phase I/II trial studies the side effects and best dose of vorinostat and to see how well it works when given together with radiation therapy followed by maintenance therapy with vorinostat in treating younger patients with newly diagnosed diffuse intrinsic pontine glioma (a brainstem tumor). Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving vorinostat together with radiation therapy may kill more tumor cells.

Eligibility Criteria

Age: >36 months and <21 years of age at the time of study enrollment

Newly diagnosed diffuse intrinsic pontine gliomas (DIPGs); biopsy proven anaplastic astrocytoma, glioblastoma multiforme, gliosarcoma, or anaplastic mixed glioma are eligible

Juvenile pilocytic astrocytoma, fibrillary astrocytoma, gangliogliomas, or other mixed gliomas without anaplasia are not eligible

Patients must have not received any prior treatment except dexamethasone and/or surgery

Adequate organ functions including bone marrow function, kidney, and liver

Patients with seizure disorder may be enrolled if on non-enzyme inducing anti-convulsants (except valproic acid) and seizures are well-controlled

Must be able to swallow capsules or liquids; patients dependent on NG tube feedings are not permitted to receive protocol therapy

Patients who have an uncontrolled infection are not eligible



Study status is:
Active, not recruiting: The study is ongoing, and participants are receiving an intervention or being examined, but potential participants are not currently being recruited or enrolled.

Principal Investigator Name

Janice Olson, MD

Contact Name

Children's Cancer and Blood Disorders Program


(503) 276-9300

Last Updated: Wednesday, January 27, 2021 11:41:12 AM